Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2014 | Editorial

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Authors: Vikas Prasad, Lisa Bodei, Mark Kidd, Irvin M. Modlin

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2014

Excerpt

One should always be cautious of undertaking a rigorous examination of a subject lest hubris interferes with balance and the confidence of “experience” undermines the rigor of facts. Notwithstanding these caveats, this missive seeks to cast a critical light on what, to date, has proven to be a contentious subject: the utility of peptide receptor radionuclide therapy (PRRT) in the management strategy of neuroendocrine tumors (NETs). Mindful of the Einsteinian adage—“whoever undertakes to set himself up as a judge of Truth and Knowledge is shipwrecked by the laughter of the gods” [1]—we propose to provide a balanced assessment of the matter from the perspective of evaluators of the therapy as opposed to purveyors. …

Einstein A. Ideas and opinions. New York: Crown; 1954.

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72. doi:10.1016/S1470-2045(07)70410-2.PubMedCrossRef

Weber HC. Medical treatment of neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 2013;20:27–31. doi:10.1097/MED.0b013e32835c034f.PubMedCrossRef

Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol 2013;40:75–83. doi:10.1053/j.seminoncol.2012.11.010.PubMedCentralPubMedCrossRef

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29:934–43. doi:10.1200/JCO.2010.33.2056.PubMedCentralPubMedCrossRef

Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:867–81. doi:10.1016/j.bpg.2013.01.004.PubMedCrossRef

Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012;42:190–207. doi:10.1053/j.semnuclmed.2012.01.002.PubMedCrossRef

Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88. doi:10.1111/j.1365-2036.2009.04174.x.PubMed

Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966–73.PubMedCrossRef

10.

Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28–47.PubMedCrossRef

11.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.PubMedCrossRef

12.

Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer 2008;112:1404–14.PubMedCrossRef

13.

Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008;113:690–700. doi:10.1002/cncr.23700.PubMedCentralPubMedCrossRef

14.

Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733–42.PubMedCrossRef

15.

Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, et al. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One 2012;7:e48411. doi:10.1371/journal.pone.0048411.PubMedCentralPubMedCrossRef

16.

Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, et al. Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 2010;24:240–9. doi:10.1210/me.2009-0321.PubMedCentralPubMedCrossRef

17.

Caplin M, Ruszniewski P, Pavel M, et al. A randomized double-blind placebo-controlled study of lanreotide antiproliferative response in patients with enteropancreatic neuroendocrine tumours (CLARINET). 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress. Amsterdam; 2013. p. Abstract E17-7103.

18.

Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett 2013;335:1–8.PubMedCrossRef

19.

Faivre S, Castellano D, Strosberg J, Gonzalez E, Salazar R. Pancreatic NETs: where do we stand now? Cancer Metastasis Rev 2014;33:361–6.CrossRef

20.

Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne PL, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16:1351–61.PubMedCrossRef

21.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268–75. doi:10.1002/cncr.25425.PubMedCrossRef

22.

Strosberg JR, Fisher GA, Benson AB, Malin JL, GEPNET Treatment Consensus Panel, Cherepanov D, Broder MS, et al. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 2013;42:397–404. doi:10.1097/MPA.0b013e31826d3a17.PubMedCrossRef

23.

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. Erratum to: the joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014;41:584. doi:10.1007/s00259-013-2454-3.CrossRef

24.

Tubiana M, Dutreix J, Wambersie A, editors. Introduction to radiobiology. Intrinsic cellular radiosensitivity, chap. 4.4. London: Taylor & Francis; 1990.

25.

Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46:92S–8S.PubMed

26.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.PubMedCrossRef

27.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.PubMedCrossRef

28.

Ruszniewski P, Ish-Shalom S, Wymenga M, O’Toole D, Arnold R, Tomassetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244–51.PubMedCrossRef

29.

Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652–9.PubMedCrossRef

30.

Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2011;52:1361–8.PubMedCrossRef

31.

Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 2009;32:360–9.PubMedCrossRef

32.

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147–56.PubMedCrossRef

33.

Kuzel T, Rosen S. Radioimmunotherapy of lymphomas and leukemias. In: Henkin R, Boles M, Dillehay G, editors. Nuclear medicine. St. Louis: Mosby; 1996. p. 594–600.

34.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46:83S–91S.PubMed

35.

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847–56.PubMedCrossRef

36.

Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med 2013;54:33–41. doi:10.2967/jnumed.112.107524.PubMedCrossRef

37.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S–6S.PubMed

38.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011;38:2125–35.PubMedCrossRef

39.

Kwekkeboom D. EANM. In: Bodei L, editor.; 2013.

40.

Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011;93:189–96. doi:10.1159/000324096.PubMedCrossRef

41.

Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 2013;54:1857–61. doi:10.2967/jnumed.112.119347.PubMedCrossRef

42.

Bodei L, Kidd M, Paganelli G, Grana C, Drozdov I, Cremonesi M, et al. Clinical features are not reliable in predicting long-term toxicity after PRRT—evidence from >800 patients to support genetic screen development. Barcelona: ENETs; 2014.

43.

Seaborg GT. My career as a radioisotope hunter. JAMA 1995;273:961–4.PubMedCrossRef

44.

Luster M, Hänscheid H, Freudenberg LS, Verburg FA. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. J Endocrinol Invest 2012;35:21–9.PubMed

45.

Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010;40:122–35. doi:10.1053/j.semnuclmed.2009.11.002.PubMedCrossRef

46.

Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;38:302–11. doi:10.1007/s00259-010-1631-x.PubMedCrossRef

47.

Giesel FL, Wulfert S, Zechmann CM, Haberkorn U, Kratochwil C, Flechsig P, et al. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy. Exp Oncol 2013;35:122–6.PubMed

48.

de Mestier L, Dromain C, d’Assignies G, Scoazec JY, Lassau N, Lebtahi R, et al. Evaluating neuroendocrine tumors progression and therapeutic response: state of the art. Endocr Relat Cancer 2013. doi:10.1530/ERC-13-0365.

49.

van Vliet EI, Krenning EP, Teunissen JJ, Bergsma H, Kam BL, Kwekkeboom DJ. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0, Tyr3]octreotate. J Nucl Med 2013;54:1689–96. doi:10.2967/jnumed.112.117408.PubMedCrossRef

50.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S–50S. doi:10.2967/jnumed.108.057307.PubMedCentralPubMedCrossRef

Title: Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths
Authors: Vikas Prasad
Lisa Bodei
Mark Kidd
Irvin M. Modlin
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2780-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2014

The 8th International Congress of the Croatian Society of Nuclear Medicine: highlights from Šibenik, 9–12 May 2014

Mycotic aneurysm of the superior mesenteric artery and other sequelae of prosthetic valve endocarditis on 18F-FDG PET/CT

Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma

Simone Waldt and Klaus Woertler (Eds): Measurements and Classifications in Musculoskeletal Radiology

Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model

Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls